WeightWatchers CEO Sima Sistani Talks Modernizing Weight Loss Management With Prescription Medication in Oprah Winfrey’s ‘Shame, Blame and the Weight Loss Revolution’

Following her departure from the WeightWatchers board of directors last month, Oprah Winfrey has explained why she decided to leave the company in her new ABC special, “Shame, Blame and the Weight Loss Revolution.” In the hourlong program, which aired on Monday, Winfrey elaborated on her usage of weight loss drugs. While she hasn’t specified which ones she used, Winfrey’s special highlighted the effects of Ozempic, Wegovy, Zepbound and Mounjaro. Oprah Winfrey on “An Oprah Special: Shame, Blame and the Weight Loss Revolution.” “I recently made the decision to not continue serving on the board of WeightWatchers,” said Winfrey, who served on the board for nearly a decade after acquiring a 10 percent stake in the company in 2015. “I made that decision because I wanted no perceived conflict of interest for this special,” she added, referring to her interview with WeightWatchers’ chief executive officer Sima Sistani. Sistani discussed WeightWatchers’ shift in strategy after purchasing Sequence, a telehealth company that specializes in prescribing weight loss medication, in 2023. Part of this shift, according to Sistani, also emphasizes reframing obesity as a disease. “We are the most clinically tested, evidence-based, science-backed behavior change program, but we were missing the third prong which was biology,” Sistani told

Follow WWD on Twitter or become a fan on Facebook.

from WWDRecent Stories https://ift.tt/CNdfy8a